Sepsis
Conditions
Keywords
Acute respiratory distress syndrome
Brief summary
The goal of this clinical trial is to learn if YD0743 works to treat sepsis-associated acute respiratory distress syndrome (ARDS) in adult patients admitted to the Intensive Care Unit. It will also learn about the safety of drug YD0743. The main questions it aims to answer are: Does YD0743 injection shorten the ventilator-using days in sepsis-associated ARDS patients? What medical problems do participants have when accepting YD0743 treatment? Researchers will compare YD0743 to a placebo (a look-alike substance that contains no active drug) to see if YD0743 works to treat sepsis-associated ARDS. Participants will: Accepting YD0743 injection at least for 7 days. Visit the clinic in person at the Day 28 to receive the follow-up check (D1 is defined as the first day starting the YD0743 or placebo treatment) .
Interventions
DRUGYD0743
Administered as a 24-hour continuous infusion via micro-infusion pump.
DRUGYD0743 Placebo
Administered as a 24-hour continuous infusion via micro-infusion pump.
Sponsors
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male or female, aged between 18 and 75 years (inclusive). * Diagnosis of sepsis. * Diagnosis of Acute Respiratory Distress Syndrome (ARDS) suspected or confirmed to be caused by sepsis. * Time from ARDS diagnosis to signing the informed consent form (ICF) does not exceed 48 hours. * The subject (or their legally authorized representative) has fully understood the study's purpose, nature, procedures, and potential adverse events, voluntarily agrees to participate, and provides written informed consent.
Exclusion criteria
* Known allergy or hypersensitivity to the active ingredient or any excipients of the investigational product; or a history of allergic disorders. * Expected survival time is less than 48 hours at the time of screening. * Sepsis with extensive burns as the primary cause. * Currently diagnosed with active malignancy; or malignancy with distant metastasis; or cancer patients with cachexia; or patients with severe organ dysfunction or visceral hemorrhage due to tumor obstruction, space-occupying effect, or compression, for whom surgical intervention is difficult or has not yet been performed. * Currently receiving or requiring Extracorporeal Membrane Oxygenation (ECMO) therapy. * Presence of chronic severe organ failure or immunodeficiency/immunosuppression. * Thrombocytopenia at screening, active/uncontrolled bleeding, or patients whom the investigator considers to have a current or prior high risk of bleeding. * Diagnosis of neutropenia. * Positive for Hepatitis B surface antigen (HBsAg) with HBV-DNA \> 1000 copies/mL or 200 IU/mL; positive for Hepatitis C virus antibody (HCV-Ab); positive for Human Immunodeficiency Virus antibody (HIV-Ab); or positive for Treponema pallidum antibody. * Participation in other drug or medical device clinical trials within 3 months prior to this study, or current participation in another clinical trial. * Pregnant or breastfeeding women, or women planning to become pregnant within the next 6 months. * Patients whose underlying primary disease cannot be effectively treated. * Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Ventilator-Free Days | Within 28 days after initiation of treatment | Number of Ventilator-Free Days within 28 Days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline and Change Rate in Oxygenation Index (PaO₂/FiO₂ Ratio) | At Day 3, Day 5, Day 8, Day 15 post first dose, or within 24 hours after the end of treatment | — |
| Change from Baseline in Driving Pressure and Static Lung Compliance in participants receiving invasive mechanical ventilation | At Day 3, Day 5, Day 8, Day 15 post first dose, or within 24 hours after end of treatment | Formulas for Driving Pressure and Static Lung Compliance: Driving Pressure (ΔP) = Plateau Pressure(Pplat) - Positive End-Expiratory Pressure (PEEP) Static Lung Compliance = Tidal Volume/(Pplat - PEEP) |
| Mortality Rate | Within 28 days after initiation of treatment | ICU Mortality Rate, In-Hospital Mortality Rate, 28-Day All-Cause Mortality Rate, and Survival Time of participants who died within 28 days |
| Number of ICU Days and Total Hospital Days | Within 28 days after initiation of treatment | — |
| Change from Baseline in Sequential Organ Failure Assessment (SOFA) Score | At Day 3, Day 5, Day 8, Day 15, Day 28 post first dose, or within 24 hours after end of treatment; | The SOFA score is a scale ranging from 0 to 24 points, with higher scores indicating worse organ function/a worse outcome. |
| Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) | Within 28 days after initiation of treatment | Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
Countries
China
Contacts
CONTACTWenJing Zhang
PRINCIPAL_INVESTIGATORBin Du, Dr.
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital
Outcome results
None listed